Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enbrel Ankylosing Spondylitis sBLA Clears FDA Cmte.; Modifying Claim Next

Executive Summary

Sponsors seeking a disease-modifying claim for an ankylosing spondylitis indication should assess the radiographic progression of the disease, FDA's Arthritis Advisory Committee agreed during its June 24 review of Amgen/Wyeth's Enbrel
Advertisement

Related Content

Enbrel Cleared For Ankylosing Spondylitis; Heart Failure Precaution Added
Enbrel Cleared For Ankylosing Spondylitis; Heart Failure Precaution Added
Ankylosing Spondylitis Guidance To Be Considered By FDA Cmte. In 2004
Ankylosing Spondylitis Guidance To Be Considered By FDA Cmte. In 2004
Merck revises Arcoxia NDA
Advertisement
UsernamePublicRestriction

Register

PS042037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel